Markus Moehler

25.8k total citations · 3 hit papers
327 papers, 8.6k citations indexed

About

Markus Moehler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Markus Moehler has authored 327 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 216 papers in Oncology, 194 papers in Pulmonary and Respiratory Medicine and 135 papers in Surgery. Recurrent topics in Markus Moehler's work include Gastric Cancer Management and Outcomes (171 papers), Colorectal Cancer Treatments and Studies (107 papers) and Esophageal Cancer Research and Treatment (69 papers). Markus Moehler is often cited by papers focused on Gastric Cancer Management and Outcomes (171 papers), Colorectal Cancer Treatments and Studies (107 papers) and Esophageal Cancer Research and Treatment (69 papers). Markus Moehler collaborates with scholars based in Germany, United States and Japan. Markus Moehler's co-authors include Peter R. Galle, Dorothea Wagner, Florian Lordick, Ines Gockel, Wilfried Grothe, Bee‐Choo Tai, Jingshan Ho, Nicholas Syn, Susanne Unverzagt and Wei Peng Yong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Markus Moehler

314 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy for advanced gastric cancer

2017 727 citations Dorothea Wagner, Markus Moehler et al. profile →
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

2013 621 citations Florian Lordick, Yoon‐Koo Kang et al. profile →
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

2018 372 citations Eric Van Cutsem, Lucjan Wyrwicz et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus Moehler Germany	48	5.1k	4.1k	2.8k	1.7k	1.2k	327	8.6k
Gary Middleton United Kingdom	41	5.4k 1.1×	4.2k 1.0×	2.0k 0.7×	1.3k 0.8×	976 0.8×	176	8.9k
Won Ki Kang South Korea	56	5.9k 1.2×	6.0k 1.5×	3.6k 1.3×	2.6k 1.5×	2.0k 1.6×	350	12.1k
Yelena Y. Janjigian United States	48	5.0k 1.0×	5.0k 1.2×	2.4k 0.9×	1.9k 1.1×	1.1k 0.9×	253	8.5k
Young Suk Park South Korea	41	4.0k 0.8×	2.3k 0.6×	1.9k 0.7×	1.3k 0.7×	436 0.4×	227	6.3k
Li‐Tzong Chen Taiwan	41	2.6k 0.5×	1.8k 0.4×	1.9k 0.7×	2.4k 1.3×	626 0.5×	296	7.3k
Franco Roviello Italy	50	2.1k 0.4×	4.8k 1.2×	3.9k 1.4×	1.4k 0.8×	1.9k 1.5×	289	8.3k
Michele Orditura Italy	44	3.4k 0.7×	2.1k 0.5×	1.2k 0.4×	1.9k 1.1×	360 0.3×	181	6.1k
Jean–François Fléjou France	50	4.3k 0.8×	2.4k 0.6×	4.8k 1.7×	1.6k 0.9×	698 0.6×	263	10.2k
Tetsuro Kubota Japan	45	2.5k 0.5×	2.7k 0.7×	1.9k 0.7×	1.6k 0.9×	1.6k 1.3×	298	6.7k
Srinivasan Madhusudan United Kingdom	43	4.3k 0.8×	2.8k 0.7×	3.6k 1.3×	3.7k 2.1×	205 0.2×	176	8.8k

Countries citing papers authored by Markus Moehler

Since Specialization

Citations

This map shows the geographic impact of Markus Moehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Moehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Moehler more than expected).

Fields of papers citing papers by Markus Moehler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Moehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Moehler. The network helps show where Markus Moehler may publish in the future.

Co-authorship network of co-authors of Markus Moehler

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Moehler. A scholar is included among the top collaborators of Markus Moehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Moehler. Markus Moehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldstein, David S., Katrin Marie Sjoquist, Sun Young Rha, et al.. (2025). LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study. Annals of Oncology. 36. S1622–S1623.

Brähler, Elmar, Jörg Wiltink, Rüdiger Zwerenz, et al.. (2024). Prevalence of current suicidal thoughts and lifetime suicide attempts in individuals with cancer and other chronic diseases in Germany: Evidence for differential associations from a representative community cohort. Journal of Affective Disorders. 367. 193–201. 1 indexed citations

Klempner, Samuel J., Matteo Fassan, Hisato Kawakami, et al.. (2024). PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays.. Journal of Clinical Oncology. 42(16_suppl). 2625–2625. 1 indexed citations

Shitara, Kohei, Yung‐Jue Bang, Lucjan Wyrwicz, et al.. (2024). Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.. Journal of Clinical Oncology. 42(16_suppl). 4073–4073. 2 indexed citations

Shitara, Kohei, Markus Moehler, Jaffer A. Ajani, et al.. (2024). Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.. Journal of Clinical Oncology. 42(16_suppl). 4040–4040. 3 indexed citations

Moehler, Markus, D-Y. Oh, Kazuyoshi Kato, et al.. (2024). 397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305. Annals of Oncology. 35. S160–S161. 7 indexed citations

Elimova, Elena, Lucjan Wyrwicz, Clara Chen, et al.. (2023). Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.. Journal of Clinical Oncology. 41(16_suppl). 4038–4038. 1 indexed citations

Bostel, Tilman, Sati Akbaba, Daniel Wollschläger, et al.. (2023). Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderly. Frontiers in Oncology. 13. 1063670–1063670. 8 indexed citations

Shah, Manish A., Jaafar Bennouna, Toshihiko Doi, et al.. (2021). KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma. Future Oncology. 17(10). 1143–1153. 78 indexed citations

10.

Stahler, Arndt, Sebastian Stintzing, Dominik Paul Modest, et al.. (2020). Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. Clinical Cancer Research. 26(24). 6559–6567. 20 indexed citations

11.

Oba, Koji, Xavier Paolettí, Yung‐Jue Bang, et al.. (2020). Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials.. Journal of Clinical Oncology. 38(15_suppl). e16506–e16506. 1 indexed citations

12.

McNamara, Mairéad G., Andre Lopes, Harpreet Wasan, et al.. (2020). Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology. 73(5). 1109–1117. 29 indexed citations

13.

Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2019). EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 19(1). 494–494. 87 indexed citations

14.

Wagner, Dorothea, Sabine Oertelt‐Prigione, Alex A. Adjei, et al.. (2019). Gender medicine and oncology: report and consensus of an ESMO workshop. Annals of Oncology. 30(12). 1914–1924. 132 indexed citations

15.

Bang, Yung‐Jue, Y. Choi, Yeul Hong Kim, et al.. (2017). Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Cancer Research. 23(19). 5671–5678. 113 indexed citations

16.

Ungerechts, Guy, Christine E. Engeland, Christian J. Buchholz, et al.. (2017). Virotherapy Research in Germany: From Engineering to Translation. Human Gene Therapy. 28(10). 800–819. 20 indexed citations

17.

Maderer, Annett, et al.. (2014). Moguntinones—New Selective Inhibitors for the Treatment of Human Colorectal Cancer. Molecular Cancer Therapeutics. 13(6). 1399–1409. 6 indexed citations

18.

Cutsem, Eric Van, Sabine Tejpar, Dirk Vanbeckevoort, et al.. (2012). Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. Journal of Clinical Oncology. 30(23). 2861–2868. 94 indexed citations

19.

Moehler, Markus, Stephan Schwarz, & Dorothea Wagner. (2011). Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy. Current Cancer Drug Targets. 11(6). 681–687. 6 indexed citations

20.

Schimanski, Carl C., Peter R. Galle, & Markus Moehler. (2008). Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World Journal of Gastroenterology. 14(30). 4721–4721. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact